Get the latest Science News and Discoveries

First patient enrolled in GOG-3133/ FRAmework-01 phase 3 study evaluating sofetabart mipitecan (LY4170156), a novel ADC targeting folate receptor alpha (FRα), in recurrent ovarian cancer - EurekAlert!

Comprehensive up-to-date news coverage, aggregated from sources all over the world by Google News.

None

Get the Android app